Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nevis Brands Inc NEVIF


Primary Symbol: C.NEVI

Nevis Brands Inc., formerly Pascal Biosciences Inc., provides cannabis brands throughout the United States. The Company provides products in Washington, Oregon, California, Ohio, Arizona and Colorado through partners and licensees. Its products include Major, which is a cannabis beverage. Major is a high-dose tetrahydrocannabinol (THC) beverage that delivers a consistent cannabis experience with no cannabis taste or smell. Major offers various flavors, such as volcanic orange mango, sunset pink lemonade, pacific coast blue raspberry, dreamin' of passion, and sacred grape. It also offers Major Minis, which is a smaller 2 ounce (oz) shot. Major Minis comes in three flavors, such as blueberry, fruit punch, and blackberry lemonade.


CSE:NEVI - Post by User

Post by Traderstock101on Dec 15, 2021 8:46am
206 Views
Post# 34232049

======> Pascal cancels $900,000 private placement <=======

======> Pascal cancels $900,000 private placement <=======

2021-12-15 02:14 ET - News Release

Mr. Patrick Gray reports

PASCAL BIOSCIENCES CANCELS PRIVATE PLACEMENT FINANCING

Pascal Biosciences Inc. has cancelled its most recent private placement. On Oct. 28, 2021, the company announced a non-brokered private placement financing of up to $900,000. Pascal has determined in light of market conditions that the current offering should be cancelled until further notice. Pascal is now looking at less dilutive financing options going forward.

About Pascal Biosciences Inc.

Pascal is a biotechnology company advancing innovative therapies for serious diseases. In addition to a targeted therapy for acute lymphoblastic leukemia, Pascal is developing cannabinoid-based treatments for cancer. These compounds include PAS-403, which is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immunostimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy to treat multiple cancers. The PAS-393 program is being developed collaboratively with SoRSE technology.

<< Previous
Bullboard Posts
Next >>